Sexual & Hormonal Health
Best Peptides for Erectile Dysfunction: Clinical Evidence (2026)
A clinical-editorial ranking of the peptides studied for erectile dysfunction — melanocortin agents (PT-141, melanotan-2) and kisspeptin — graded honestly against the AUA first-line standard. No peptide is FDA-approved for ED.
PT-141Melanotan-2KisspeptinPDE5 inhibitorsMale sexual health
The quick verdict
The peptides studied for ED — melanocortin agents and kisspeptin — ranked by human evidence and graded honestly against PDE5 inhibitors, the AUA first-line standard. No peptide is FDA-approved for ED.
- Best overall
- First-line PDE5 inhibitors (not a peptide) — For an actual patient with ED in 2026, the evidence-based answer is a cardiometabolic/hormonal workup plus AUA first-line PDE5 inhibitors. No peptide has out-performed them in a head-to-head trial, and none is FDA-approved for ED.
- Best value
- Bremelanotide (PT-141) — Of the peptides, PT-141 has the deepest human male-ED dataset (multiple Phase 2 trials, hundreds of men) and a defined, characterized safety profile — though its male-ED program was halted over blood pressure and it is unapproved for men.
- Best for Men whose primary deficit is low desire/arousal rather than blood flow
- Kisspeptin-54 (investigational, research-only) — The one mechanistic RCT targeting the desire/arousal component used IV kisspeptin-54 and was well tolerated with no cardiovascular changes — the most interesting emerging signal, but surrogate-endpoint and not a treatment.
How we evaluated
We ranked peptides by the strength of human clinical evidence specifically for erectile dysfunction or male sexual function — not by marketing popularity or preclinical mechanism. Human data below RCT level or from small, surrogate, or Phase 1–2 trials caps at Grade B; there is no Grade A peptide for male ED. We weighted safety heavily because the ED population overlaps with cardiovascular disease, and because one entrant has caused permanent, PDE5i-unresponsive ED. PDE5 inhibitors (the AUA first-line standard) frame the comparison. This is informational and editorial content — not medical advice, and not a sourcing guide.
- Human evidence quality. Depth and design of human ED/sexual-function trials — RCT vs open-label, sample size, real clinical endpoint vs surrogate (e.g. tumescence to video), replication.
- Regulatory status. FDA approval for ED (none exists), approval for adjacent indications, and legality of sale — from FDA labels and primary regulatory sources.
- Condition-specific safety. Risks that matter for the ED population specifically: blood-pressure effects, priapism, and contraindication in the cardiovascular disease that often underlies ED.
- Mechanistic plausibility. Whether the peptide plausibly addresses a real ED mechanism (central desire/arousal) versus overlapping with proven peripheral PDE5 action.
Rating scale: 1–5 stars weighted toward human evidence quality and condition-specific safety; grade reflects the strength of human data for ED (A supportive human RCTs/meta; B human below-RCT/small/surrogate/Phase 1–2; C preclinical only; D anecdotal/marketing or catastrophic safety; X unclear).
Last verified .
At a glance
| # | Name | Evidence | Rating | Best for | Pricing |
|---|---|---|---|---|---|
| 1 | Bremelanotide (PT-141) | B | 3.0 | Understanding the strongest peptide candidate for the ED mechanism — while recognizing it is off-label, unapproved for men, and carries a cardiovascular contraindication | Varies by pharmacy |
| 2 | Kisspeptin (kisspeptin-54 / kisspeptin-10) | B | 2.5 | Following the most scientifically interesting emerging signal for low male desire — as investigational research, not treatment | Not commercially validated |
| 3 | Melanotan-2 (MT-II) | D | 1.0 | Understanding why unregulated melanocortins are dangerous for ED — as a cautionary example, never as a therapy | Not a legitimate product |
| 4 | PDE5 inhibitors (reference standard — not a peptide) | A | 4.5 | The evidence-based first-line choice for most men with ED — the benchmark the peptides are compared against | Widely available, often low-cost generic |
| 5 | Compounded kisspeptin-10 (consumer form) | ? | 1.0 | Recognizing the gap between marketing claims and evidence — the consumer form has no controlled ED data | Varies; not validated for ED |
Bremelanotide (PT-141)
Deepest human male-ED dataset — yet unapproved for ED and stopped for blood pressure
Bremelanotide (PT-141) is a synthetic alpha-MSH analogue that agonizes central melanocortin-3 and -4 receptors, triggering a pro-erectile, pro-arousal output independent of the peripheral nitric-oxide/PDE5 pathway. It has the deepest human clinical-trial dataset of any peptide for ED. PT-141 was originally developed as an ED drug: a double-blind, placebo-controlled Phase 1 trial of intranasal PT-141 found a statistically significant erectile response versus placebo at doses above 7 mg, with onset around 30 minutes. Palatin Technologies ran four ED trials, culminating in a 2008 Phase 2b in sildenafil non-responders in which a clinically meaningful response was seen in 33.5% of treated men versus 8.5% on placebo — real, replicated Phase 2 human ED evidence, hence Grade B. But the intranasal formulation produced variable absorption and dose-dependent blood-pressure increases; the FDA halted the trials in 2007 and Palatin discontinued the program in 2008, pivoting to subcutaneous dosing for female HSDD. That female product (Vyleesi) gained FDA approval in 2019 — for desire in women, not erections in men. The blood-pressure signal is intrinsic to the molecule, and the label contraindicates use in uncontrolled hypertension or known cardiovascular disease — precisely the population enriched among men with ED.
Strengths
- Deepest human male-ED dataset of any peptide — multiple Phase 2 trials, hundreds of men
- Central mechanism (MC4R) is independent of PDE5, so it could in principle help PDE5 non-responders
- Well-characterized safety profile from an FDA-approved (female) product; defined adverse-event list
Weaknesses
- Not FDA-approved for male ED — approval is for female HSDD only; male program discontinued in 2008
- Transiently raises blood pressure (~6/3 mmHg) and is contraindicated in cardiovascular disease, which overlaps heavily with the ED population
- No Phase 3 ED program; male use rests on the discontinued Phase 2 data, and common effects include nausea, flushing and injection-site reactions
- Best for
- Understanding the strongest peptide candidate for the ED mechanism — while recognizing it is off-label, unapproved for men, and carries a cardiovascular contraindication
- Pricing
- Varies by pharmacy
Source: Diamond LE et al., Int J Impot Res 2004 (PMID 14963471)
Kisspeptin (kisspeptin-54 / kisspeptin-10)
Most interesting emerging signal for low desire — one small surrogate-endpoint RCT
Kisspeptin is the master upstream regulator of reproductive hormones, but it also appears to act directly on limbic and sexual-processing brain circuits — offering a route to the desire/arousal component of ED rather than penile hemodynamics. In a double-blind, placebo-controlled, two-way crossover RCT, 32 men with hypoactive sexual desire disorder received an intravenous infusion of kisspeptin-54 (1 nmol/kg/h for 75 minutes) versus rate-matched placebo. Kisspeptin significantly increased penile tumescence to erotic video (up to 56% more than placebo, P=.02), increased self-reported happiness about sex, and modulated the brain's sexual-arousal network on fMRI — with no adverse events and no significant blood-pressure or heart-rate changes, a favorable contrast to the melanocortins. The authors framed it as early promise of a potential first pharmacological treatment for men with low sexual desire. But this is single-study, surrogate-endpoint (tumescence to video, not real-world ED resolution), n=32, IV-only evidence, hence Grade B at the lower edge. A crucial nuance: the trial used kisspeptin-54, the longer endogenous form — not the shorter kisspeptin-10 fragment usually marketed and compounded, which has a much shorter half-life and no controlled ED efficacy data. Extrapolating the result to subcutaneous kisspeptin-10 is an unproven leap.
Strengths
- Directly targets the desire/arousal deficit that PDE5 inhibitors do not address
- High-quality, well-designed double-blind crossover RCT design with an fMRI mechanistic readout
- Excellent short-term tolerability — no adverse events and no cardiovascular changes in the controlled study
Weaknesses
- Single small study (n=32) using a surrogate endpoint (tumescence to video), not real-world ED resolution
- IV kisspeptin-54 in a research setting only — no validated outpatient dose or route
- The commonly sold kisspeptin-10 fragment was not tested and has no controlled ED efficacy data
- Best for
- Following the most scientifically interesting emerging signal for low male desire — as investigational research, not treatment
- Pricing
- Not commercially validated
Melanotan-2 (MT-II)
Real 10-man erectogenic signal — but unapproved, illegal, and cause of permanent priapism-induced ED
Melanotan-2 is PT-141's parent compound and the source of the entire melanocortin-for-erection story — but it is an unapproved, illegally sold drug that has caused permanent erectile dysfunction. The foundational human ED study is a double-blind, placebo-controlled crossover RCT in 10 men with psychogenic ED: subcutaneous MT-II at 0.025 mg/kg produced clinically apparent erections in 8 of 10 men, with mean duration of over-80%-tip rigidity of 38.0 minutes on MT-II versus 3.0 minutes on placebo (P=0.0045), monitored by RigiScan. That is a genuine — if tiny and decades-old — human signal, which is why the effect alone would grade B. But safety grades D, and safety is the decisive point. MT-II is sold illegally online mainly as a tanning agent, and its central MC3R/MC4R activity causes spontaneous erections and, dangerously, priapism. A 55-year-old man developed a 30-hour ischemic priapism after a single 2-mg subcutaneous injection; despite aspiration, phenylephrine and operative penoscrotal decompression, at 15-week follow-up he had erectile dysfunction unresponsive to PDE5 inhibitors. Additional cases include melanotan-induced ischemic priapism requiring cavernosal aspiration and systemic toxicity such as rhabdomyolysis and renal dysfunction. Gray-market product purity and identity are unverifiable, so even the studied dose is not reproducible. The cruel irony for ED: a drug taken to cause erections can cause priapism that destroys erectile function permanently. It is not a viable ED therapy — it is the cautionary tale that motivated the cleaner analogue PT-141.
Strengths
- A genuine, if tiny, controlled human erectogenic signal (10-man 1998 RCT, 8 of 10 responders)
- Central MC3R/MC4R mechanism is independent of the peripheral PDE5 pathway
- Historically important — it is the parent molecule that led to PT-141's development
Weaknesses
- Documented to cause 30-hour ischemic priapism resulting in permanent, PDE5i-unresponsive ED
- Unapproved anywhere and illegal to sell; gray-market product purity and identity are unverifiable
- Additional serious harms reported: rhabdomyolysis, renal dysfunction, plus broader melanocortin risks (melanoma/atypical nevi)
- Best for
- Understanding why unregulated melanocortins are dangerous for ED — as a cautionary example, never as a therapy
- Pricing
- Not a legitimate product
Source: Mallory C et al., Sexual Medicine 2021 (priapism → permanent ED)
PDE5 inhibitors (reference standard — not a peptide)
The AUA first-line therapy the peptides are measured against
PDE5 inhibitors — sildenafil (Viagra), tadalafil (Cialis), vardenafil and avanafil — are not peptides, but they are the honest benchmark every peptide in this ranking must be measured against, so they belong here explicitly. They act at the very last step of the erectile cascade, blocking breakdown of cyclic GMP to prolong nitric-oxide-driven smooth-muscle relaxation and penile blood flow. They are the American Urological Association first-line therapy for ED, with an enormous, well-characterized safety record accumulated across tens of millions of men and decades of use. Their limitation is real and defines the conceptual space peptides try to occupy: they do nothing for desire and require the upstream arousal/nitric-oxide cascade to fire, which is why they fail in a meaningful subset of men — those with diabetic neuropathy, post-prostatectomy nerve injury, or low desire. That gap is exactly where centrally-acting peptides are mechanistically appealing. But conceptually complementary is not the same as approved, safe and proven: no peptide has out-performed PDE5 inhibitors in a head-to-head ED trial, none is FDA-approved for ED, and the peptides carry either blood-pressure effects or catastrophic priapism risk. PDE5 inhibitors are absolutely contraindicated with nitrates, and combining any pro-erectile agent without physician supervision raises hypotension and priapism risk.
Strengths
- AUA-recommended first-line therapy with a vast, well-characterized safety record
- Oral, on-demand dosing used by tens of millions of men over decades
- Directly addresses the peripheral blood-flow step; the proven standard every peptide is measured against
Weaknesses
- Does nothing for desire and requires the upstream arousal/nitric-oxide cascade to fire, so it fails in a meaningful subset of men
- Absolutely contraindicated with nitrates; requires the peripheral pathway to be intact
- Not a peptide — included here as the honest reference standard, not as a peptide option
- Best for
- The evidence-based first-line choice for most men with ED — the benchmark the peptides are compared against
- Pricing
- Widely available, often low-cost generic
Source: Burnett AL et al., AUA Erectile Dysfunction Guideline, J Urol 2018
Compounded kisspeptin-10 (consumer form)
The marketed fragment — same receptor, but no controlled ED data and an unproven extrapolation
Kisspeptin-10 is the shorter C-terminal decapeptide — the form usually marketed and compounded for consumers — and it is listed separately here precisely because it is frequently confused with the kisspeptin-54 that generated the only human sexual-arousal signal. Kisspeptin-10 shares the same receptor (KISS1R) and core bioactivity in reproductive-endocrine studies, but it has a much shorter half-life and, critically, was not the molecule tested in the ED/arousal RCT. The compounded subcutaneous kisspeptin-10 protocols circulating commercially are not derived from any ED efficacy trial; they are extrapolations from the kisspeptin-54 infusion study and from reproductive-hormone work. That extrapolation is an unproven leap: a different molecule, a different pharmacokinetic profile, and a different route (subcutaneous versus the studied IV infusion). Consequently the consumer kisspeptin-10 form has no controlled ED efficacy data and should be regarded as grade X — genuinely unclear, not preliminarily positive — for any erectile-dysfunction claim until it is actually tested. We rank it last because a same-family molecule with a plausible receptor rationale but zero controlled ED data, marketed on the borrowed credibility of a different peptide's single trial, is exactly the pattern that misleads consumers. Anyone interested in the kisspeptin mechanism should follow the kisspeptin-54 research, not assume the marketed decapeptide inherits its results.
Strengths
- Shares the KISS1R receptor and core reproductive-endocrine bioactivity with kisspeptin-54
- Mechanistic rationale for the desire/arousal pathway is at least plausible
- Was well tolerated in reproductive-endocrine research contexts (short-term)
Weaknesses
- No controlled ED efficacy data — the human arousal RCT used kisspeptin-54, not this fragment
- Much shorter half-life than kisspeptin-54; the marketed subcutaneous protocols are unvalidated extrapolations
- Often marketed on the borrowed credibility of a different peptide's single trial — an unproven leap
- Best for
- Recognizing the gap between marketing claims and evidence — the consumer form has no controlled ED data
- Pricing
- Varies; not validated for ED
Source: Mills EG et al., JAMA Network Open 2023 (used kisspeptin-54, not -10)
Frequently asked
Are any peptides FDA-approved for erectile dysfunction?
No. As of 2026 no peptide is FDA-approved for erectile dysfunction. Bremelanotide (PT-141), sold as Vyleesi, is FDA-approved only for premenopausal women with acquired, generalized hypoactive sexual desire disorder — a different sex and diagnosis. Its male-ED program was halted by the FDA in 2007 over blood-pressure lability and discontinued in 2008. Melanotan-2 and kisspeptin have no approval for any sexual indication. Marketing that calls PT-141 an FDA-approved ED drug conflates the female HSDD approval with male ED. The evidence-based first-line therapy remains oral PDE5 inhibitors under medical supervision.
Is PT-141 better than Viagra for erectile dysfunction?
No head-to-head trial shows that, and PT-141 is not even approved for ED. PDE5 inhibitors are the AUA first-line therapy with an enormous, well-characterized safety record. PT-141 acts centrally on arousal rather than penile blood flow, so it is conceptually complementary — it was studied in sildenafil non-responders, where a 2008 Phase 2b reported a clinically meaningful response in 33.5% of treated men versus 8.5% on placebo. But that male-ED program was discontinued in 2008 over blood-pressure safety, and PT-141 remains Grade B, off-label and unapproved for men. It is not a proven upgrade over PDE5 inhibitors.
Can melanotan-2 give me firmer erections?
A single 10-man 1998 randomized crossover trial did show melanotan-2 initiated erections in psychogenic ED, with over-80%-tip-rigidity duration of 38 minutes on MT-II versus 3 minutes on placebo. But that effect must be weighed against catastrophic risk: melanotan-2 is unapproved, illegal to sell, of unverifiable purity, and documented to cause ischemic priapism. One reported case involved a 30-hour priapism after a single 2-mg injection that left the man with erectile dysfunction unresponsive to PDE5 inhibitors even after surgery. The drug taken to cause erections can permanently destroy them. It is not a viable ED therapy.
Does kisspeptin treat erectile dysfunction?
Not proven. One well-designed double-blind crossover RCT in 32 men with low sexual desire found that IV kisspeptin-54 increased penile tumescence to erotic video by up to 56% versus placebo, increased happiness about sex, and modulated the brain's sexual-processing network on fMRI, with no adverse events. That is a genuinely promising signal, but it is a single, small, surrogate-endpoint, intravenous-only study using kisspeptin-54 — not real-world ED resolution, and not the shorter kisspeptin-10 fragment sold commercially. It grades B as an early signal for low desire, not an established erectile-dysfunction treatment.
Are peptides a safer alternative to Viagra or Cialis?
Not supported by the evidence. PDE5 inhibitors are the AUA first-line standard with a vast, well-characterized safety record built over decades and tens of millions of men. The peptides carry meaningful risks instead: the melanocortins (PT-141, melanotan-2) transiently raise blood pressure and are contraindicated in the cardiovascular disease that often underlies ED, and melanotan-2 has caused catastrophic priapism leading to permanent ED. No peptide has out-performed PDE5 inhibitors in a head-to-head ED trial. From a functional, root-cause view, the highest-yield actions are a real medical workup and addressing upstream vascular, metabolic and hormonal drivers — not swapping a proven pill for an injectable with a worse risk profile.
My erectile dysfunction is new — should I try a peptide?
New-onset ED warrants a medical evaluation, not self-treatment. Erectile dysfunction is frequently the first visible sign of cardiovascular, diabetic, hormonal, sleep or psychological disease, and addressing those upstream drivers plus first-line PDE5 inhibitors when appropriate is the evidence-based path. The melanocortin peptides are additionally contraindicated in exactly the cardiovascular disease that often underlies ED, because they transiently raise blood pressure. From a functional, root-cause perspective, ED is usually a downstream message rather than a standalone disease, so a real workup — cardiovascular, glycemic, lipid, testosterone, thyroid, sleep, medication review — is the highest-yield first step.